Chromosome 3 is a valid marker for prognostic testing of biopsy material from uveal melanoma later treated by brachytherapy. (17th February 2019)

• Record Type: Journal Article
• Authors: Le Guin, Claudia Helga Dorothee; Metz, Klaus Alfred; Lehmann, Nils; Kreis, Stefan Horst; Bornfeld, Norbert; Rudolf Lohmann, Dietmar; Zeschnigk, Michael
• Is Part Of: Biomarkers. Volume 24:Number 2(2019)
• Page Start: 134
• Page End: 140
• Publication Date: 2019-02-17
• Subjects: Uveal melanoma -- prognosis -- biopsy -- monosomy 3 -- disomy 3; Biochemical markers -- Periodicals; 610.28
• DOI: 10.1080/1354750X.2018.1517827
• Languages: English
• ISSNs: 1354-750X

Abstract

Abstract: Purpose: Monosomy 3 (M3) in uveal melanoma (UM) obtained after enucleation is significantly associated with metastatic death. With improved biopsy techniques, samples from patients treated with eye-preserving methods have become available. As the choice of treatment depends on tumour size, patients treated with eye-preserving brachytherapy tend to have smaller tumours. It has to be determined if M3 is a valid marker for prognosis of these patients. Methods: Follow-up and clinical data were collected from a total of 451 UM patients: 291 patients were treated by brachytherapy. Tumour tissue was sampled by transretinal biopsy using the 23-gauge Essen biopsy forceps prior to therapy in 114 of them. Chromosome 3 status was determined by microsatellite analysis. Data were compared to those from 160 patients treated by enucleation. Results: Chromosome 3 status correlates significantly with disease-related survival in both patient groups. The proportion of tumours with M3 is lower in the brachytherapy group compared to patients treated with enucleation (25/77 32% and 102/144 71%, respectively). Conclusions: M3 is a valid marker for poor prognosis in uveal melanoma later treated by brachytherapy. The higher proportion of D3 tumours might explain, at least in part, the more favourable prognosis of patients treated by brachytherapy.